



Cite this: *New J. Chem.*, 2016,
40, 7573

Catalyst-free Biginelli-type synthesis of new functionalized 4,7-dihydropyrazolo-[1,5-*a*]pyrimidines†

Maksim A. Kolosov,^a Dmitriy A. Beloborodov,^a Valeriy D. Orlov^a and Victor V. Dotsenko^{*bc}

The Biginelli-type reaction of 5-amino-3-arylpypyrazole-4-carbonitriles with aldehydes and 1,3-dicarbonyl compounds was studied in detail. We found that the reaction requires no catalysts and proceeds in boiling DMF to give 2-aryl-6-RC(O)-4,7-dihydropyrazolo[1,5-*a*]pyrimidin-3-carbonitriles in good yields. The reaction of aminopyrazoles with dicarbonyls leading to 6-unsubstituted pyrazolo[1,5-*a*]pyrimidines proceeds competitively and becomes the dominant process under acid-promoted conditions. 2-Aryl-8-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazolin-3-carbonitriles were obtained under catalyst-free conditions in up to 80% yields starting from 5-amino-3-arylpypyrazole-4-carbonitriles, aldehydes and 1,3-cyclohexanedione.

Received (in Montpellier, France)
31st January 2016,
Accepted 6th July 2016

DOI: 10.1039/c6nj00336b

www.rsc.org/njc

1. Introduction

In the last two decades, the classical urea-based multicomponent reaction named after Italian chemist Pietro Biginelli, as well as the reactions of so-called Biginelli compounds (3,4-dihydropyrimidin-2(1*H*)-ones and -thiones) have attracted great attention (for recent reviews see ref. 1–9). Less attention is paid to the non-classical Biginelli-type reaction employing aminoazoles as *N,N*-dinucleophilic components.^{9–13} This approach is well suited for combinatorial chemistry, providing a diversity of di-, tri- and tetrazolopyrimidines. Our interests have been focused on the chemistry of unusual Biginelli-type compounds¹⁴ and, particularly, on the chemistry of pyrazolo- and triazolo[1,5-*a*]pyrimidines.¹⁵

Pyrazolo[1,5-*a*]pyrimidines are important scaffolds which are present in many synthetic drugs such as dorsomorphin¹⁶ or other bone morphogenetic protein receptor inhibitors useful for treatment of anemia, muscular dystrophy, atherosclerosis, etc.¹⁷ Pyrazolo[1,5-*a*]pyrimidines also have been recognized as purine analogs with c-AMP phosphodiesterase inhibitory activity,¹⁸ and as tyrosine kinase inhibitors.¹⁹ 4,7-Dihydropyrazolo[1,5-*a*]pyrimidines (DPPMs) behave as potent mimics of Hantzsch 1,4-dihydropyridine calcium channel

blockers²⁰ and related pyrazolo[5,1-*b*]quinazolines were found to be potent *K_{ATP}* channel openers.²¹

Two most commonly used approaches to build the 4,7-dihydropyrazolo[1,5-*a*]pyrimidine core are known. The first one consists of the reaction of 3(5)-aminoazoles with α,β -unsaturated carbonyls (for reviews see ref. 11–13, 22) and the other is based on the modified Biginelli reaction of 3(5)-aminoazoles with aldehydes and active methylene carbonyl compounds^{9–13} (Scheme 1).

When attempting to use 3(5)-aminopyrazoles with no substituents at the C-4 position, one may encounter the problem of a dual reactivity of these heterocycles. Thus, 3(5)-aminopyrazoles may react either as straight urea-type *N,N*-binucleophiles leading to the expected DPPMs,^{9,12} or as a masked enamine species – *C,N*-binucleophiles to afford 4,7-dihydropyrazolo[3,4-*b*]pyridines^{12,23,24} (Scheme 2).

The problem of chemoselectivity in this context could be solved in two different ways – either by using selected reaction conditions (e.g., pH of reaction media, different catalysts and solvents, sonication or microwave irradiation) to modulate the selectivity,^{23–25} or, – by blocking the C-4 position in aminopyrazoles with a protecting group.^{24–27} From this point of view, easily available^{15a} 5-aminopyrazole-4-carbonitriles could be considered as prospective reagents bearing the reactive


^a Department of Organic Chemistry, V.N. Karazin Kharkiv National University, Svobody sq., 4, 61022 Kharkiv, Ukraine

^b Department of Organic Chemistry and Technologies, Kuban State University, 149 Stavropolskaya str., 350040 Krasnodar, Russian Federation.


E-mail: victor_dotsenko@bigmir.net

^c Department of Chemistry, North Caucasus Federal University, 1a Pushkin St., 355009 Stavropol, Russian Federation

† Electronic supplementary information (ESI) available: Spectral data. See DOI: [10.1039/c6nj00336b](https://doi.org/10.1039/c6nj00336b)



Scheme 1 General approaches to the synthesis of dihydroazolopyrimidines.

Scheme 2 The reactions of aminopyrazoles with α,β -unsaturated carbonyls.


cyano group at C-4, which may react under Biginelli conditions to afford functionalized heterocycles. In the present paper, we have studied the reaction of 5-amino-3-arylpyrazole-4-carbonitriles with active methylene 1,3-dicarbonyls and aldehydes with the aim to develop a synthetic route toward DPPMs.

2. Results and discussion

As a model reaction, we examined the reaction of 5-amino-3-phenylpyrazole-4-carbonitrile **1a** with benzaldehyde **2A** and *N*-(4-chlorophenyl)-3-oxobutanamide **3a** (Scheme 3) in boiling DMF with no catalysts. As expected, the reaction proceeds smoothly to give DPPM **4a**. In order to optimize the reaction conditions, we studied the effects of solvent amount, reaction time, reagents ratio and different work-up procedures on the yield of the target product **4a**.


The best yield of pure **4a** (60% after recrystallization) was obtained when the reagents were taken in equimolar amounts and the reaction was conducted in a three-component mode. The best results were obtained when minimum amounts of DMF (0.5 mL per \sim 2 mmol of each reagent) were used, under short term heating (\sim 20 min) and with a final precipitation of the product by addition of MeOH. Meanwhile, the reaction **1a** + **2a** + **3a** in boiling EtOH under acid catalyzed conditions (HCl) proceeds in a quite different way to give pyrazolo[1,5-*a*]-pyrimidine-5(4*H*)-one-3-carbonitrile **5** in 35% yield. According to the NMR data for crude pyrazolopyrimidine **4a**, product **5** is also the main by-product of the uncatalyzed process.

With the optimized procedure described above, the analogs of compound **4a** were obtained in 32–53% yields (Table 1). However, we failed to obtain DPPMs **4** by ternary condensation of aminopyrazole **1b** with aldehydes and 2,4-pentanedione. Instead, the sole isolated product was 5,7-dimethylpyrazolo[1,5-*a*]-pyrimidine-3-carbonitrile **6** as the result of the reaction of **1b** with 2,4-pentanedione alone (Scheme 4). It is noteworthy that the reaction proceeds notwithstanding the conditions of temperature or the acidity of the reaction media.

Scheme 3 Synthesis of pyrazolopyrimidines **4** and **5**.Table 1 Synthesis of DPPMs **4b–g**

Entry	Product	Ar	R	R ¹	Yield ^a (%)
1	4b	4-MeC ₆ H ₄	Ph	4-ClC ₆ H ₄ NH	37
2	4c	Ph	4-NO ₂ C ₆ H ₄	4-ClC ₆ H ₄ NH	52
3	4d	4-MeC ₆ H ₄	4-NMe ₂ C ₆ H ₄	4-ClC ₆ H ₄ NH	32
4	4e	4-MeC ₆ H ₄	Ph	OEt	53

^a The yields are given for pure products after recrystallization from MeOH.


Scheme 4 Synthesis of compounds **4f** and **6**.

In contrast, unsaturated diketone **7** reacts with aminopyrazole **1b** to afford the desired DPPM **4f** in a good yield. In order to find the optimal conditions, we attempted to combine the preparation of starting endione **7** and Biginelli-type condensation in a one-pot procedure. Thus, when PhCHO and Ac₂CH₂ were briefly heated in DMF to give condensation product **7** followed by treatment with aminopyrazole **1b**, compound **4f** was obtained in 65% yield. Using the same approach, ethyl acetoacetate was converted into 4,7-dihydropyrazolo[1,5-*a*]pyrimidine **4e** in 53% yield.

The obtained observations allowed us to draw some tentative conclusions about how this Biginelli-type reaction proceeds in a three-component mode. We suggest that the reaction proceeds first by Knoevenagel reaction of an aldehyde with an active methylene compound, probably catalyzed either by aminopyrazole **1** which is basic enough, or DMF. Next, the uncatalyzed reaction of the formed condensation product with aminopyrazole leads to the formation of target compounds **4** (Scheme 5). The presumable formation of aza-Michael adduct **8** as an intermediate in the suggested mechanism is in agreement with previously reported data.^{11,22}

It should be noted that, despite the known benefits of base-catalyzed Biginelli-type reactions (Atwal modification,²⁸ Bakibaev and Filimonov protocol²⁹) or non-catalyzed protocols,^{7,14b,30} most methods commonly used for the synthesis of Biginelli compounds require an acid as a catalyst.^{6–9} In our previous paper⁷ it was proposed as a joke that sodium chloride could be used as the “catalyst” for reactions that proceed quite efficiently without any additives and catalysts (the term “chemical placebo”





Scheme 5 Probable mechanistic pathway for the synthesis of DPPMs 4.

was introduced by us⁷ to define a compound that is evidently ineffective as a catalyst but has to be added anyway, probably for non-scientific reasons or tradition). Recently, a detailed paper³¹ appeared in which conditions for Biginelli reaction were critically discussed. *Inter alia*, the authors reasonably doubted that NaCl could be an effective catalyst and claimed that “there is no reasonable doubt of the importance of catalysis for the Biginelli reaction, and the role of the catalyst is not only to facilitate the formation of the final product but also to select a preferred reaction pathway”. We have to admit that the above Biginelli-type reaction may proceed without any additional catalysts, at least in certain cases. In the present case, an acid catalyst strongly disfavors formation of the desired Biginelli products. Nevertheless, HCl was found to be a good catalyst for the reaction between aminopyrazoles **1a** and 1,3-dicarbonyls.



The obtained results encouraged us to continue our studies with other dicarbonyl compounds. Thus, dihydrosresorcinol (1,3-cyclohexanedione) reacts with aminopyrazoles **1a,b** and aldehydes to give the expected 2-aryl-8-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitriles **8a-d** (Table 2).

In order to examine the reactivity of the synthesized compounds, we unsuccessfully attempted to carry out thiolysis by passing H₂S for 24 h through the DMF solution of compound **8a** in the presence of Et₃N. One may suggest that the deprotonation of N(4)H in a basic medium causes the formation of a highly mesomerically stabilized anion (Scheme 6) so the HS⁻ anion should attack a negatively charged substrate which is unfavorable for thiolysis. The low reactivity of the cyano group toward the HS⁻ anion might well be a consequence of tautomerism which involves the delocalization of the negative charge onto the cyano group. In order to confirm this

Table 2 Synthesis of compounds **8a-d**

Entry	Product	Ar	R ¹	Yield ^a (%)
1	8a	4-MeC ₆ H ₄	Ph	80
2	8b	4-MeC ₆ H ₄	4-Me ₂ NC ₆ H ₄	56
3	8c	4-MeC ₆ H ₄	Et	62
4	8d	Ph	4-MeC ₆ H ₄	47

^a The yields are given for pure products after recrystallization from MeOH.

Scheme 6 Possible mesomeric mechanism for stabilization of the negative charge for anions of **8**.Scheme 7 The synthesis and thiolysis of compound **9**.

suggestion, we synthesized the *N*(4)-alkyl derivative **9** by treatment of **8a** with EtBr in KOH-H₂O-MeCN system. It was found that compound **9** undergoes thiolysis under the same conditions to yield thioamide **10** (Scheme 7). Given these results, we may conclude that successful modification of the functionality at C(3) leading to compounds like **10** could be performed using protective groups (e.g., MOM^{14d}) at the *N*(4) position, which could be easily removed later.

3. Conclusions

In conclusion, we have developed a simple and selective synthetic protocol based on the Biginelli-type multicomponent reaction of 5-amino-3-arylpypyrazole-4-carbonitriles with aldehydes and 1,3-dicarbonyl compounds. The reported method provides catalyst-free access to functionalized 4,7-dihydropyrazolo[1,5-*a*]pyrimidine-3-carbonitriles and 4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazolin-3-carbonitriles which could be further transformed by *N*-alkylation or thiolysis. In certain cases the Biginelli reaction competes with the side process of the formation of pyrazolo[1,5-*a*]pyrimidines by reaction of aminopyrazole and dicarbonyl components without the participation of an aldehyde. The latter reaction predominates in the presence of an acid catalyst, whereas the Biginelli-type reaction proceeds clearly without any catalysts in pure DMF.

4. Experimental

4.1 Materials and methods

¹H NMR spectra were recorded on a Bruker Avance 400 spectrometer (400 MHz) and on a Varian Mercury VX-200 spectrometer (200 MHz) in DMSO-*d*₆ with TMS as the internal standard. Chemical shifts are given in ppm, coupling constants are given in Hz. ¹³C NMR spectra were recorded on a Bruker Avance 500

spectrometer (125 MHz) and on a Bruker Avance 400 spectrometer (100 MHz) in DMSO-*d*₆ with TMS as the internal standard. Mass spectra (EI, 70 eV) were obtained on a Varian 1200L instrument using a direct probe exposure (DEP) method. IR spectra were recorded in KBr pellets using a Perkin Elmer Spectrum One FT-IR spectrometer. Elemental analyses were obtained using a EuroEA-3000 instrument. Melting points were determined using a Köfler hot-stage apparatus. DMF was distilled under reduced pressure and stored under molecular sieves (4 Å). The purity of the compounds was checked using TLC (Merck ALUGRAM Xtra SIL G/UV 254 plates) with EtOAc/hexane mixtures as eluents. 5-Amino-3-arylpnazole-4-carbonitriles **1a** and **b** were obtained by a reported procedure.^{15a} H₂S gas was produced by water hydrolysis of Al₂S₃ and dried by passing its flow through the layer of Al₂S₃. Starting aldehydes, 1,3-dicarbonyl compounds and solvents are commercially available.

4.2 General process for preparation of pyrazolopyrimidines **4a–g** and pyrazoloquinazolines **8a–d**

A mixture of the appropriate aldehyde (2.2 mmol), 1,3-dicarbonyl compound (2 mmol) and the corresponding aminopiazole **1** (2 mmol) in DMF (0.5 mL) was heated under reflux for 20 min. The mixture was cooled and MeOH (20 mL) was added. The precipitate was filtered off and washed with MeOH (3 × 3 mL).

N-(4-Chlorophenyl)-3-cyano-5-methyl-2,7-diphenyl-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-6-carboxamide 4a. White solid, mp 327–329 °C, ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.44 (br. s, 1H, NH), 9.96 (br. s, 1H, NH), 7.67–7.82 (m, 2H, ArH), 7.56 (d, *J* = 9.0, 2H, ArH), 7.37–7.50 (m, 3H, ArH), 7.15–7.37 (m, 7H, ArH), 6.56 (s, 1H, C(7)H), 2.21 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 165.15, 151.52, 144.49, 141.11, 138.38, 136.09, 131.22, 129.85, 129.40, 129.18, 129.02, 128.72, 127.42, 127.35, 126.51, 121.62, 114.97, 105.13, 70.85, 60.78, 17.49; IR (KBr, cm^{−1}) ν_{max} 1495, 1511, 1590, 1603, 1631, 1667, 2226, 2922, 3060, 3270 (br.); MS (*m/z*, EI, 70 eV): 467 (M^(³⁷Cl)⁺, 3%), 465 (M^(³⁵Cl)⁺, 9%), 339 (34%), 311 (56%), 235 (63%), 153 (55%), 127 (100%). Anal. calcd for C₂₇H₂₀ClN₅O (465.14): C, 69.60; H, 4.33; N, 15.03%. Found: C, 69.79; H, 4.14; N, 14.86%.

N-(4-Chlorophenyl)-3-cyano-5-methyl-2-(4-methylphenyl)-7-phenyl-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-6-carboxamide 4b. White solid, mp 332–334 °C (MeOH, decomp.); ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.44 (br. s, 1H, NH), 9.96 (br. s, 1H, NH), 7.64 (d, *J* = 7.8, 2H, ArH), 7.55 (d, *J* = 8.8, 2H, ArH), 7.10–7.42 (m, 9H, ArH), 6.54 (s, 1H, C(7)H), 2.30 (s, 3H, CH₃), 2.21 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.17, 151.57, 144.42, 141.15, 139.43, 138.38, 136.08, 129.88, 129.14, 128.99, 128.67, 128.49, 127.50, 127.35, 126.40, 121.64, 115.05, 105.14, 70.69, 60.75, 21.35, 17.48; IR (KBr, cm^{−1}) ν_{max} 1494, 1509, 1590, 1602, 1630, 2224, 2917, 3028, 3130, 3270 (br.) cm^{−1}; MS (*m/z*, EI, 70 eV): 481 (M^(³⁷Cl)⁺, 8%), 479 (M^(³⁵Cl)⁺, 20%), 353 (100%), 325 (39%), 155 (33%), 127 (90%). Anal. calcd for C₂₈H₂₂ClN₅O (479.96): C, 70.07; H, 4.62; N, 14.59%. Found: C, 69.91; H, 4.40; N, 14.40%.

N-(4-Chlorophenyl)-3-cyano-5-methyl-7-(4-nitrophenyl)-2-phenyl-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-6-carboxamide 4c. White solid, mp 317–319 °C (MeOH, decomp.); ¹H NMR

(400 MHz, DMSO-*d*₆) δ 10.67 (br. s, 1H, NH), 10.00 (br. s, 1H, NH), 8.17 (d, *J* = 8.8, 2H, ArH), 7.65–7.80 (m, 2H, ArH), 7.37–7.63 (m, 7H, ArH), 7.31 (d, *J* = 8.8, 2H, ArH), 6.69 (s, 1H, C(7)H), 2.22 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ (125 MHz, DMSO-*d*₆) 164.85, 151.94, 147.92, 147.80, 144.51, 138.19, 136.77, 131.02, 129.97, 129.39, 129.04, 128.81, 127.65, 126.56, 124.45, 121.71, 114.79, 104.14, 71.24, 60.14, 17.63; IR (KBr, cm^{−1}) ν_{max} 1348, 1493, 1521, 1629, 2227, 2853, 2923, 3269 (br.); MS (*m/z*, EI, 70 eV): 510 (M^(³⁵Cl)⁺, 2%), 384 (9%), 242 (100%), 127 (34%). Anal. calcd for C₂₇H₁₉ClN₅O₃ (510.93): C, 63.47; H, 3.75; N, 16.45%. Found: C, 63.70; H, 3.77; N, 16.31%.

N-(4-Chlorophenyl)-3-cyano-7-(4-dimethylaminophenyl)-5-methyl-2-(4-methylphenyl)-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-6-carboxamide 4d. White solid, mp 311–313 °C (MeOH, decomp.); ¹H NMR (500 MHz, DMSO-*d*₆) δ 10.38 (br. s, 1H, NH), 9.91 (br. s, 1H, NH), 7.67 (d, *J* = 8.0, 2H, ArH), 7.60 (d, *J* = 9.0, 2H, ArH), 7.33 (d, *J* = 8.5, 2H, ArH), 7.28 (d, *J* = 8.0, 2H, ArH), 7.09 (d, *J* = 8.5, 2H, ArH), 6.62 (d, *J* = 9.0, 2H, ArH), 6.45 (s, 1H, C(7)H), 2.84 (s, 6H, N(CH₃)₂), 2.34 (s, 3H, CH₃), 2.24 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.34, 151.25, 150.66, 144.13, 139.31, 138.53, 135.90, 129.86, 128.97, 128.93, 128.64, 128.47, 128.30, 127.36, 126.35, 126.30, 121.60, 121.54, 115.17, 112.54, 105.41, 70.40, 60.29, 21.36, 17.45; IR (KBr, cm^{−1}) ν_{max} 1494, 1520, 1600, 1633, 1667, 2221, 2799, 2919, 3273 (br.); MS (*m/z*, EI, 70 eV): 510 (M^(³⁷Cl)⁺, 9%), 508 (M^(³⁵Cl)⁺, 22%), 382 (100%), 354 (41%), 198 (24%), 127 (37%). Anal. calcd for C₃₀H₂₇ClN₆O (523.03): C, 68.89; H, 5.20; N, 16.07%. Found: C, 69.01; H, 5.25; N, 15.89%.

Ethyl 3-cyano-5-methyl-2-(4-methylphenyl)-7-phenyl-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-6-carboxylate 4e. White solid, mp 239–241 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.95 (br. s, 1H, NH), 7.62 (d, *J* = 8.0, 2H, ArH), 7.10–7.40 (m, 7H, ArH), 6.25 (s, 1H, C(7)H), 3.97 (q, *J* = 7.0, 2H, CH₂), 2.45 (s, 3H, CH₃), 2.30 (s, 3H, CH₃), 1.06 (t, *J* = 7.0, 3H, CH₂CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 165.36, 151.76, 145.61, 143.11, 142.36, 139.47, 129.87, 128.97, 128.51, 128.33, 127.49, 126.41, 114.73, 98.96, 71.55, 60.07, 60.06, 21.35, 18.43, 14.40; IR (KBr, cm^{−1}) ν_{max} 1551, 1571, 1594, 1645, 1704, 2224, 2930, 2989, 3107, 3252 (br.); MS (*m/z*, EI, 70 eV): 398 (M⁺, 61%), 369 (20%), 321 (100%), 293 (44%), 103 (26%), 91 (31%). Anal. calcd for C₂₄H₂₂N₄O₂ (398.46): C, 72.34; H, 5.57; N, 14.06%. Found: C, 72.95; H, 5.70; N, 13.83%.

2-(4-Methylphenyl)-8-oxo-9-phenyl-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile 8a. White solid, mp 329–331 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 11.32 (br. s, 1H, NH), 7.63 (d, *J* = 8.2, 2H, ArH), 6.95–7.20 (m, 7H, ArH), 6.21 (s, 1H, C(9)H), 2.56–2.86 (m, 2H, CH₂), 2.12–2.40 (m, 2H, CH₂), 2.30 (s, 3H, CH₃), 1.70–2.10 (m, 2H, CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 193.38, 151.23, 150.89, 142.65, 141.43, 139.14, 129.51, 128.49, 127.92, 127.43, 127.09, 126.02, 114.27, 107.50, 71.68, 57.83, 36.35, 26.08, 20.97, 20.65; IR (KBr, cm^{−1}) ν_{max} 1571, 1585, 1643, 1721, 2223, 2918, 3199 (br.), 3249; MS (*m/z*, EI, 70 eV): 380 (M⁺, 7%), 312 (34%), 199 (35%), 149 (100%), 115 (30%). Anal. calcd for C₂₄H₂₀N₄O (380.44): C, 75.77; H, 5.30; N, 14.73%. Found: C, 75.54; H, 5.12; N, 14.53%.

9-(4-Dimethylaminophenyl)-2-(4-methylphenyl)-8-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile 8b. White solid, mp 299–301 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 11.18



(br. s, 1H, NH), 7.64 (d, J = 6.8, 2H, ArH), 7.24 (d, J = 6.8, 2H, ArH), 7.03 (d, J = 7.2, 2H, ArH), 7.57 (d, J = 7.2, 2H, ArH), 6.09 (s, 1H, C(9)H), 2.56–3.00 (m, 2H, CH₂), 2.80 (s, 6H, N(CH₃)₂), 2.18–2.37 (m, 2H, CH₂), 2.30 (s, 3H, CH₃), 1.75–2.06 (m, 2H, CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 193.74, 151.39, 150.79, 150.47, 142.90, 139.41, 129.87, 129.53, 128.43, 128.13, 126.38, 114.79, 112.48, 108.32, 71.80, 57.73, 36.85, 26.47, 21.37, 21.14; IR (KBr, cm^{−1}) ν _{max} 1524, 1569, 1615, 1643, 2230, 2798, 2944, 3102, 3165 (br.), 3233, 3502 (br.); MS (*m/z*, EI, 70 eV): 422 (M⁺, 100%), 395 (26%), 304 (30%), 211 (11%), 120 (36%), 91 (32%). Anal. calcd for C₂₆H₂₅N₅O (423.51): C, 73.74; H, 5.95; N, 16.54%. Found: C, 73.56; H, 6.13; N, 16.35%.

9-Ethyl-2-(4-methylphenyl)-8-oxo-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile 8c. White solid, mp 224–226 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.89 (br. s, 1H, NH), 7.71 (d, J = 8.0, 2H, ArH), 7.28 (d, J = 8.0, 2H, ArH), 5.29 (s, 1H, C(9)H), 2.53–2.72 (m, 2H, CH₂), 2.18–2.42 (m, 2H, CH₂), 2.33 (s, 3H, CH₃), 1.58–2.10 (m, 4H, 2CH₂), 0.56 (t, J = 7.0, 3H, CH₂CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 194.31, 152.46, 151.38, 143.80, 139.42, 129.90, 128.52, 126.43, 114.76, 105.68, 71.57, 55.65, 36.91, 27.04, 26.48, 21.38, 21.22, 7.92; IR (KBr, cm^{−1}) ν _{max} 1443, 1568, 1588, 1640, 2216, 2934, 3105, 3181 (br.), 3245, 5322 (br.); MS (*m/z*, EI, 70 eV): 332 (M⁺, 12%), 303 (100%), 116 (13%), 91 (20%). Anal. calcd for C₂₀H₂₀N₄O (332.40): C, 72.27; H, 6.06; N, 16.86%. Found: C, 72.49; H, 5.87; N, 16.70%.

9-(4-Methylphenyl)-8-oxo-2-phenyl-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile 8d. White solid, mp 309–311 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 10.77 (br. s, 1H, NH), 7.63–7.82 (m, 2H, ArH), 7.33–7.52 (m, 3H, ArH), 7.12 (d, 2H, J = 8.0, ArH), 7.06 (d, J = 8.0, 2H, ArH), 6.17 (s, 1H, C(9)H), 2.60–2.84 (m, 2H, CH₂), 2.20 (s, 3H, CH₃), 2.12–2.34 (m, 2H, CH₂), 1.74–2.05 (m, 2H, CH₂); ¹³C NMR (100 MHz, DMSO-*d*₆) δ 193.76, 151.51, 151.12, 143.10, 139.00, 137.63, 131.06, 129.88, 129.42, 129.37, 127.41, 126.50, 114.63, 108.03, 72.19, 58.04, 36.78, 26.48, 21.13, 21.08; IR (KBr, cm^{−1}) ν _{max} 1443, 1543, 1574, 1588, 1645, 2217, 2947, 3198, 3247, 3468 (br.); MS (*m/z*, EI, 70 eV): 380 (M⁺, 100%), 365 (18%), 352 (31%), 289 (49%), 91 (61%), 77 (92%). Anal. calcd for C₂₄H₂₀N₄O (380.44): C, 75.77; H, 5.30; N, 14.73%. Found: C, 75.93; H, 5.41; N, 14.72%.

4.3 Synthesis of 6-acetyl-5-methyl-2-(4-methylphenyl)-7-phenyl-4,7-dihydropyrazolo[1,5-*a*]pyrimidine-3-carbonitrile 4f

Method A. A mixture of 3-benzylidene-2,4-pentanedi one (0.38 g, 2 mmol) and aminopyrazole **1b** (0.40 g, 2 mmol) in DMF (0.5 mL) was heated under reflux for 0.5 h. The mixture was cooled and MeOH (20 mL) was added. The precipitate was filtered off and washed with MeOH (3 \times 3 mL) to give compound **4f**. Yield 60%, white solid, mp 258–260 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 7.63–7.82 (m, 2H, ArH), 7.33–7.52 (m, 3H, ArH), 7.12 (d, J = 8.0, 2H, ArH), 7.06 (d, J = 8.0, 2H, ArH), 6.17 (s, 1H, C(9)H), 2.60–2.84 (m, 2H, CH₂), 2.20 (s, 3H, CH₃), 2.12–2.34 (m, 2H, CH₂), 1.74–2.05 (m, 2H, CH₂); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 195.05, 151.76, 145.16, 142.76, 141.76, 139.49, 129.90, 129.16, 128.67, 128.36, 127.71, 126.42, 114.72, 108.96, 71.60, 59.86, 30.98, 21.36, 19.51; IR (KBr, cm^{−1}) ν _{max} 1443, 1549, 1569, 1581, 1624, 2225, 2938, 3028, 3178, 3239, 3285, 3502 (br.); MS (*m/z*, EI, 70 eV): 368 (M⁺, 67%), 353 (33%),

325 (21%), 291 (55%), 91 (37%), 43 (100%). Anal. calcd for C₂₃H₂₀N₄O (368.43): C, 74.98; H, 5.47; N, 15.21%. Found: C, 75.00; H, 5.29; N, 15.07%.

Method B. A mixture of PhCHO (0.23 g, 2 mmol) and 2,4-pentanedi one (0.2 g, 2 mmol) in DMF (0.5 mL) was heated under reflux for 20 min. Then aminopyrazole **1b** (0.4 g, 2 mmol) was added and the mixture was heated under reflux for an additional 20 min. The mixture was cooled and MeOH (20 mL) was added. The precipitate was filtered off and washed with MeOH (3 \times 3 mL) to give pyrazolopyrimidine **4f** (yield 65%). The melting point, EA, IR and NMR data are identical to those of the above sample. When ethyl acetoacetate (2 mmol) was used instead of 2,4-pentanedi one, pyrazolopyrimidine **4e** was obtained in 53% yield.

4.4 Synthesis of 7-methyl-5-oxo-2-phenyl-4,5-dihydropyrazolo[1,5-*a*]pyrimidine-3-carbonitrile 5

A mixture of *N*-(4-chlorophenyl)-3-oxobutanamide (0.42 g, 2 mmol), 3-aminopyrazole **1a** (0.37 g, 2 mmol), PhCHO (0.23 g, 2 mmol) and 3 drops of conc. HCl in EtOH (3 mL) was heated under reflux for 30 min. The mixture was cooled, the precipitate was filtered off and washed with MeOH (3 \times 3 mL) to give pyrazolopyrimidine **5** as a white solid. Yield 35%, mp > 320 °C (subl.) [Lit.³² mp > 330 °C]; ¹H NMR (200 MHz, DMSO-*d*₆) δ 13.35 (br. s, 1H, NH), 7.85–8.05 (m, 2H, ArH), 7.45–7.65 (m, 3H, C(7)H), 5.88 (s, 1H, C(6)H), 2.33 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 154.96, 153.16, 151.74, 146.78, 130.35, 130.29, 129.18, 126.97, 113.61, 98.90, 72.31, 18.67; IR (KBr, cm^{−1}) ν _{max} 1446, 1574, 1626, 1661, 2227, 2844, 2953, 2988, 3063 (br.), 3141, 3292; MS (*m/z*, EI, 70 eV): 250 (M⁺, 100%), 221 (51%), 193 (11%), 127 (27%), 62 (20%). Anal. calcd for C₁₄H₁₀N₄O (250.26): C, 67.19; H, 4.03; N, 22.39%. Found: C, 67.34; H, 3.99; N, 22.40%.

4.5 Synthesis of 5,7-dimethyl-2-(4-methylphenyl)pyrazolo[1,5-*a*]pyrimidine-3-carbonitrile 6

A mixture of 2,4-pentanedi one (0.38 g, 2 mmol), PhCHO (0.23 g, 2 mmol) and aminopyrazole **1b** (0.40 g, 2 mmol) in DMF (0.5 mL) was heated under reflux for 30 min. The mixture was cooled and MeOH (20 mL) was added. The precipitate of the product was filtered off and washed with MeOH (3 \times 3 mL) to give product **6** as a yellow solid. Yield 48%, mp 229–231 °C (MeOH); ¹H NMR (200 MHz, DMSO-*d*₆) δ 7.91 (d, J = 8.0, 2H, ArH), 7.33 (d, J = 8.0, 2H, ArH), 7.09 (s, 1H, C(6)H), 2.72 (s, 3H, CH₃), 2.56 (s, 3H, CH₃), 2.37 (s, 3H, CH₃); ¹³C NMR (125 MHz, DMSO-*d*₆) δ 163.65, 155.70, 151.83, 147.58, 140.72, 130.13, 128.05, 127.24, 115.10, 112.32, 112.30, 24.76, 21.48, 16.88; IR (KBr, cm^{−1}) ν _{max} 1440, 1556, 1626, 2212, 2923, 3445; MS (*m/z*, EI, 70 eV): 262 (M⁺, 100%), 246 (9%), 234 (7%), 128 (9%), 90 (37%), 65 (43%). Anal. calcd for C₁₆H₁₄N₄ (262.31): C, 73.26; H, 5.38; N, 21.36%. Found: C, 73.25; H, 5.49; N, 21.19%. When the same reaction was conducted in AcOH or EtOH–HCl, compound **6** was obtained in 90 and 94% yield.

4.6 Preparation of 4-methyl-2-(4-methylphenyl)-8-oxo-9-phenyl-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbonitrile 9

A mixture of compound **8a** (4.07 g, 10.7 mmol), EtBr (7.0 g, 4.75 mL, 64 mmol) and saturated aq. KOH solution (5.3 mL) in MeCN (30 mL) was heated under reflux for 1 h. The mixture was



cooled and poured into 400 mL of brine. The resulting mixture was extracted with EtOAc (3 × 70 mL), dried with Na_2SO_4 and then evaporated to give a yellow precipitate, which was recrystallized from EtOH to give pure compound **9** as a pale-yellow solid, yield 60%, mp 207–209 °C (EtOH); ^1H NMR (400 MHz, DMSO- d_6) δ 7.61 (d, J = 8.0, 2H, ArH), 7.15–7.29 (m, 7H, ArH), 6.25 (s, 1H, C(9)H), 4.01–4.25 (m, 2H, CH_2CH_3), 2.92–3.02 (m, 1H, CH_2), 2.64–2.74 (m, 1H, CH_2), 2.29 (s, 3H, CH_3), 2.18–2.36 (m, 2H, CH_2), 1.96–2.06 (m, 1H, CH_2), 1.77–1.92 (m, 1H, CH_2); 1.36 (t, J = 6.8, 3H, CH_2CH_3); ^{13}C NMR (100 MHz, DMSO- d_6) δ 193.99, 152.63, 152.24, 143.32, 141.61, 139.63, 129.88, 128.97, 128.42, 128.14, 127.32, 126.81, 115.66, 109.87, 73.40, 57.70, 42.05, 36.04, 24.69, 21.38, 20.90, 15.23; IR (KBr, cm^{-1}) ν_{max} 1399, 1538, 1614, 1645, 2210, 2951, 3022; MS (m/z , EI, 70 eV): 408 (M^+ , 100%), 379 (65%), 331 (62%), 303 (40%), 91 (35%). Anal. calcd for $\text{C}_{26}\text{H}_{24}\text{N}_4\text{O}$ (408.49): C, 76.45%; H, 5.92%; N, 13.72%. Found: C, 76.50%; H, 6.12%; N, 13.67%.

4.7 Synthesis of 4-methyl-2-(4-methylphenyl)-8-oxo-9-phenyl-4,5,6,7,8,9-hexahydropyrazolo[5,1-*b*]quinazoline-3-carbothioamide **10**

A slow stream of dry H_2S was passed through a solution of compound **9** (0.5 g, 1.22 mmol) in a mixture of Et_3N (10 mL) and DMF (10 mL) for 48 h (controlled by TLC) at 50 °C (bath temperature). The mixture turned green-yellow. After cooling, the mixture was poured into cold water (300 mL) and the pH was adjusted to 7.0 with diluted (3%) HCl. The precipitate formed was filtered off and washed with plenty of water. Compound **10** was obtained in 40% yield as a pale-yellow solid, mp 235–237 °C; ^1H NMR (200 MHz, DMSO- d_6) δ 10.17 (br. s, 1H, NH_2), 9.84 (br. s, 1H, NH_2), 7.56 (d, J = 8.0, 2H, ArH), 7.13–7.35 (m, 5H, ArH), 7.13 (d, J = 8.0, 2H, ArH), 6.23 (s, 1H, C(9)H), 4.00–4.35 (m, 2H, CH_2CH_3), 2.85–3.05 (m, 1H, CH_2), 2.56–2.75 (m, 1H, CH_2), 2.27 (s, 3H, CH_3), 2.13–2.40 (m, 2H, CH_2), 1.70–2.10 (m, 2H, CH_2), 1.25 (t, J = 7.0, 3H, CH_2CH_3); ^{13}C NMR (100 MHz, DMSO- d_6) δ 197.77, 193.70, 153.56, 146.08, 142.44, 137.66, 134.56, 130.37, 129.23, 128.80, 128.05, 127.29, 127.16, 109.38, 108.16, 57.23, 41.81, 36.16, 25.24, 21.31, 21.14, 15.76; IR (KBr, cm^{-1}) ν_{max} 1360, 1423, 1539, 1593, 1622, 2928, 3059, 3223 (br.); MS (m/z , EI, 70 eV): 442 (M^+ , 100%), 413 (80%), 409 (48%), 379 (60%), 320 (37%), 256 (25%), 105 (23%), 73 (29%). Anal. calcd for $\text{C}_{26}\text{H}_{26}\text{N}_4\text{OS}$ (442.58): C, 70.56%; H, 5.92%; N, 12.66%. Found: C, 70.55%; H, 6.10%; N, 12.48%.

Acknowledgements

We thank V. V. Vashchenko, E. V. Vashchenko, V. I. Musatov (STC “Institute for Single Crystals” NAS of Ukraine, Kharkov) and Enamine Ltd for spectroscopic measurements. V. V. D. is grateful for financial support by the Russian Ministry of Education and Science (State Assignment to Higher Education Institutions, project no. 547).

Notes and references

- D. Dallinger, A. Stadler and C. O. Kappe, *Pure Appl. Chem.*, 2004, **76**, 1017.
- C. O. Kappe, *Acc. Chem. Res.*, 2000, **33**, 879.

- C. O. Kappe, *Eur. J. Med. Chem.*, 2000, **35**, 1043.
- C. O. Kappe, *QSAR Comb. Sci.*, 2003, **22**, 630.
- M. Matache, C. Dobrota, N. D. Bogdan and D. P. Funeriu, *Curr. Org. Synth.*, 2011, **8**, 356.
- Suresh, J. S. Sandhu, *ARKIVOC*, 2012, (i), 66.
- M. A. Kolosov, V. D. Orlov, D. A. Beloborodov and V. V. Dotsenko, *Mol. Diversity*, 2009, **13**, 5.
- S. V. Vdovina and V. A. Mamedov, *Russ. Chem. Rev.*, 2008, **77**, 1017.
- J.-P. Wan and Y. Liu, *Synthesis*, 2010, 3943.
- Y. V. Sedash, N. Yu. Gorobets, V. A. Chebanov, I. S. Konovalova, O. V. Shishkin and S. M. Desenko, *RSC Adv.*, 2012, **2**, 6719.
- V. A. Chebanov, S. M. Desenko and T. W. Gurley, *Azaheterocycles Based on a,b-Unsaturated Carbonyls*, Springer, 2008.
- V. A. Chebanov, K. A. Gura and S. M. Desenko, *Top. Heterocycl. Chem.*, 2010, **23**, 41.
- V. A. Chebanov and S. M. Desenko, *Curr. Org. Chem.*, 2006, **10**, 297.
- (a) M. A. Kolosov, O. G. Kulyk, M. J. K. Al-Ogaili and V. D. Orlov, *Tetrahedron Lett.*, 2015, **56**, 4666; (b) M. A. Kolosov, O. G. Kulyk, D. A. Beloborodov and V. D. Orlov, *J. Chem. Res.*, 2013, 115; (c) M. A. Kolosov, V. D. Orlov, V. V. Vashchenko, S. V. Shishkina and O. V. Shishkin, *Collect. Czech. Chem. Commun.*, 2007, **72**, 1219; (d) M. A. Kolosov, O. G. Kulyk, E. G. Shvets and V. D. Orlov, *Synth. Commun.*, 2014, **44**, 1649; (e) M. A. Kolosov, O. G. Kulyk, M. J. K. Al-Ogaili and V. D. Orlov, *Z. Naturforsch. B: J. Chem. Sci.*, 2012, **67b**, 921; (f) M. A. Kolosov, M. J. K. Al-Ogaili, V. S. Parkhomenko and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2013, **49**, 1484; (g) M. A. Kolosov and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2008, **44**, 1418; (h) M. A. Kolosov and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2007, **43**, 1349; (i) M. A. Kolosov, O. G. Kulyk, O. I. Starchenko and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2013, **49**, 1166.
- (a) M. A. Kolosov, D. A. Beloborodov, O. G. Kulyk and V. D. Orlov, *J. Heterocycl. Chem.*, 2014, **51**(S1), E89; (b) M. A. Kolosov, E. G. Shvets, O. G. Kulyk and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2015, **51**, 1052; (c) M. A. Kolosov, M. J. K. Al-Ogaili, O. G. Kulyk and V. D. Orlov, *Chem. Heterocycl. Compd.*, 2015, **51**, 691.
- P. B. Yu, C. C. Hong, C. Sachidanandan, J. L. Babbitt, D. Y. Deng, S. A. Hoyng, H. Y. Lin, K. D. Bloch and R. T. Peterson, *Nat. Chem. Biol.*, 2008, **4**, 33.
- D. W. Engers, A. Y. Frist, C. W. Lindsley, C. C. Hong and C. R. Hopkins, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 3248.
- M. H. Elnagdi, M. R. H. Elmoghayar and G. H. Elgemeie, *Adv. Heterocycl. Chem.*, 1987, **41**, 320.
- R. R. Frey, M. L. Curtin, D. H. Albert, K. B. Glaser, L. J. Pease, N. B. Soni, J. J. Bouska, D. Reuter, K. D. Stewart, P. Marcotte, G. Bukofzer, J. Li, S. K. Davidsen and M. R. Michaelides, *J. Med. Chem.*, 2008, **51**, 3777.
- K. S. Atwal and S. Moreland, *Bioorg. Med. Chem. Lett.*, 1991, **1**, 291.
- I. Drizin, M. W. Holladay, L. Yi, H. Q. Zhang, S. Gopalakrishnan, M. Gopalakrishnan, K. L. Whiteaker, S. A. Buckner, J. P. Sullivan and W. A. Carroll, *Bioorg. Med. Chem. Lett.*, 2002, **12**, 1481.



22 S. M. Desenko and V. D. Orlov, *Azagereterotsikly na osnove aromaticheskikh nepredelnykh ketonov (Azaheterocycles based on aromatic unsaturated ketones)*, Folio, Kharkov, Ukraine, ISBN: 966-03-0518-4, 1998 (in Russian).

23 V. A. Chebanov, V. E. Saraev, S. M. Desenko, V. N. Chernenko, I. V. Knyazeva, U. Groth, T. N. Glasnov and C. O. Kappe, *J. Org. Chem.*, 2008, **73**, 5110.

24 V. A. Chebanov, Y. I. Sakhno, S. M. Desenko, V. N. Chernenko, V. I. Musatov, S. V. Shishkina, O. V. Shishkin and C. O. Kappe, *Tetrahedron*, 2007, **63**, 1229.

25 E. A. Muravyova, S. M. Desenko, R. V. Rudenko, S. V. Shishkina, O. V. Shishkin, Y. V. Sen'ko, E. V. Vashchenko and V. A. Chebanov, *Tetrahedron*, 2011, **67**, 9389.

26 Y. I. Sakhno, S. V. Shishkina, O. V. Shishkin, V. I. Musatov, E. V. Vashchenko, S. M. Desenko and V. A. Chebanov, *Mol. Diversity*, 2010, **14**, 523.

27 V. A. Chebanov, V. E. Saraev, S. V. Shishkina, O. V. Shishkin, V. I. Musatov and S. M. Desenko, *Eur. J. Org. Chem.*, 2012, 5515.

28 (a) B. C. O'Reilly and K. S. Atwal, *Heterocycles*, 1987, **26**, 1185; (b) K. S. Atwal, B. C. O'Reilly, J. Z. Gougoutas and M. F. Malley, *Heterocycles*, 1987, **26**, 1189; (c) K. S. Atwal, G. C. Rovnyak, B. C. O'Reilly and J. Schwartz, *J. Org. Chem.*, 1989, **54**, 5898.

29 A. A. Bakibaev and V. D. Filimonov, *J. Org. Chem. USSR*, 1991, **27**, 736.

30 M. A. Kolosov, V. D. Orlov and Yu. M. Vasil'eva, *Kharkov Univ. Bull. Chem. Ser.*, 2006, **731**, 69 (in Russian).

31 H. G. O. Alvim, T. B. Lima, A. L. de Oliveira, H. C. B. de Oliveira, F. M. Silva, F. C. Gozzo, R. Y. Souza, W. A. da Silva and B. A. D. Neto, *J. Org. Chem.*, 2014, **79**, 3383.

32 E. M. Zayed, S. A. S. Ghozlan and A.-A. H. Ibrahim, *Monatsh. Chem.*, 1984, **115**, 431.

